Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

CNS Involvement In A Patient with Waldenstrom’s Macroglobulinemia-A Diagnostic Challenge

Ambuga Badari, MBBS, James Miller, PA, Gerald L. Logue, MD, Zale P Bernstein, MD

Blood (2011) 118 (21): 4595.

https://doi.org/10.1182/blood.V118.21.4595.4595

Published: 2011

Journal Articles

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Howard A Liebman, MD, Mansoor N Saleh, MD, James B Bussel, MD, Zale P Bernstein, MD, O George Negrea, MD, Anthony C Onyegbula, DO, Charles M Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2011) 118 (21): 3302.

https://doi.org/10.1182/blood.V118.21.3302.3302

Published: 2011

Journal Articles

Inhibitor Eradication In Acquired Factor VIII Inhibitor: A Case Series

Ambuga Badari, MBBS, Zale P Bernstein, MD, Gerald L. Logue, MD, Anush Patel, MBBS, MD, James Miller, PA, Tan Tran, Chandana Keshavamurthy

Blood (2010) 116 (21): 1423.

https://doi.org/10.1182/blood.V116.21.1423.1423

Published: 2010

Journal Articles

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Mansoor N Saleh, MD, Howard Liebman, MD, Zale P. Bernstein, MD, O. George Negrea, MD, James B. Bussel, MD, Anthony C. Onyegbula, DO, Charles M Farber, MD, PhD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Kenneth Pennington, MD, Heather Horne, Nick Teoh, PhD, Asraf Gomaa, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2009) 114 (22): 1322.

https://doi.org/10.1182/blood.V114.22.1322.1322

Published: 2009

Journal Articles

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

Umeer Ashraf, MD, Ritika Mahajan, MBBS, Theresa Hahn, PhD, Shannon L Smiley, MD, Philip L. McCarthy, MD, Zale P. Bernstein, MD, Asher Alban Chanan-Khan, MD, Minoo Battiwala, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2008) 112 (11): 1138.

https://doi.org/10.1182/blood.V112.11.1138.1138

Published: 2008

Journal Articles

Lack of Impact on Platelet Increments by Number of Apheresis Platelet Units Transfused

Anush Patel, MD, Zale P. Bernstein, MD, James Kepner, Anil Patel, MD, Manmeet S Ahluwalia, MD, Joanne L Becker, MD

Blood (2008) 112 (11): 4073.

https://doi.org/10.1182/blood.V112.11.4073.4073

Published: 2008

Journal Articles

Photopheresis in HIV-1 Infected Patients Utilizing (Benzoporphyrin Derivative Verteporfin/BPD-MA) and Light.

Zale P. Bernstein, MD, Thomas Dougherty, PhD, Sandra Gollnick, Stanley Schwartz, MD, Supriya Mahajan, James Kepner, Adam Sumlin, Carleton Stewart, Paul Wallace, Harold Walder, Bernard Poiesz, MD

Blood (2007) 110 (11): 2275.

https://doi.org/10.1182/blood.V110.11.2275.2275

Published: 2007

Journal Articles

Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Sikander Ailawadhi, MD, Francisco J. Hernandez-Ilizaliturri, MD, Loretta Miner, NP, Zale P. Bernstein, MD, Asher Chanan-Khan, MD, Kena C. Miller, MSN NP, Alice Mohr, FNP, Petr Starostik, MD, Myron S. Czuczman, MD, Swaminathan Padmanabhan, MD

Blood (2007) 110 (11): 4433.

https://doi.org/10.1182/blood.V110.11.4433.4433

Published: 2007

Journal Articles

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Swaminathan Padmanabhan, MD, Anjana Elefante, PharmD, Prakash Varadarajan, MD, Minoo Battiwalla, MD, Arvinder Bir, MD, Theresa Hahn, PhD, Shannon Smiley, MD, Francisco J. Hernandez-Illizalitturi, MD, Loretta Miner, RNP, Alice Mohr, RNP, Zale P. Bernstein, MD, Asher Chanan-Khan, MD, Philip McCarthy, Jr., MD, Myron Czuczman, MD

Blood (2007) 110 (11): 5130.

https://doi.org/10.1182/blood.V110.11.5130.5130

Published: 2007

Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity.

Myron S. Czuczman, MD, Marion Skipper, Alice Mohr, NP, Zale P. Bernstein, MD, Francisco J. Hernandez-Ilizaliturri, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 1369.

https://doi.org/10.1182/blood.V110.11.1369.1369

Published: 2007

Journal Articles

Clinical Outcomes of Off-Label Use of Recombinant Activated Factor VII (rFVIIa) at Teaching Hospitals Affiliated with a Medical School.

Yijun Cheng, MD, Melissa S. Baxter, PharmD, Walter S. Schroeder, PharmD, Zale P. Bernstein, MD

Blood (2006) 108 (11): 4033.

https://doi.org/10.1182/blood.V108.11.4033.4033

Published: 2006

Journal Articles

Photopheresis in HIV-1 Infected Patients (Pt) Using Benzoporphyrin Derivative (BPD-MA) Induces Apoptosis in CD4 Cells, Increases Cytolytic T-Cell Activity, Intracellular Expression of Chemokines, and Decreases HIV Infectivity and Viral Load.

Zale P. Bernstein, MD, Thomas Dougherty, Stanley Schwartz, Sandra Gollnick, Carleton Stewart, Harold Walder, M.P.N. Nair, S.D. Mahajan, Adam Sumlin, Bernard Poiesz

Blood (2006) 108 (11): 1257.

https://doi.org/10.1182/blood.V108.11.1257.1257

Published: 2006

Journal Articles

Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin (Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with Relapsed (rel) or Refactory (ref) Multiple Myeloma.

Asher Alban Chanan-khan, MD, Swaminathan Padmanabhan, MD, Kena C. Miller, RNP, Laurie Musiel, RNP, Jihnhee Yu, Ph.D, Zale P. Bernstein, MD, Rami Manochakian, MD, Myron S. Czuczman, MD

Blood (2006) 108 (11): 3539.

https://doi.org/10.1182/blood.V108.11.3539.3539

Published: 2006

Journal Articles

Assessment of Menorrhagia in Females Followed for Bleeding Disorders at the Hemophilia Center of Western New York-Correlation between Clinical Presentation and Laboratory Parameters.

Eric E. Bush, MD, James Kepner, Shannon Smiley, MD, Linda Belling, Zale P. Bernstein, MD

Blood (2006) 108 (11): 3984.

https://doi.org/10.1182/blood.V108.11.3984.3984

Published: 2006

Journal Articles

Assessment of Menorrhagia in Females Followed for Bleeding Disorders at the Hemophilia Center of Western New York-Correlation between Clinical Presentation and Laboratory Parameters.

Eric Bush, MD, Shannon Smiley, MD, Linda Belling, Zale P. Bernstein, MD

Blood (2005) 106 (11): 4054.

https://doi.org/10.1182/blood.V106.11.4054.4054

Published: 2005

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Patricia Marshall, Swaminathan Padmanabhan, MD, William Brady, Zale P. Bernstein, MD, Paul Wallace, MD, Myron S. Czuczman, MD

Blood (2005) 106 (11): 2974.

https://doi.org/10.1182/blood.V106.11.2974.2974

Published: 2005

Journal Articles

Photopheresis in HIV-1 Infected Patients (pt) Using Benzoporphyrin Derivative (BPD-MA) Induces Apoptosis in CD4 Cells, Increases Intracellular Expression of Chemokines and Decreases HIV Infectivity and Viral Load.

Zale P. Bernstein, MD, Thomas Dougherty, Stanley A. Schwartz, MD, Sandra Gollnick, Carlton Stewart, MD, Harold Walder, M. P. Nair, S. D. Mahajan, Adam Sumlin, Patricia Marhsall, Bernard Poiesz, MD

Blood (2005) 106 (11): 1431.

https://doi.org/10.1182/blood.V106.11.1431.1431

Published: 2005

Journal Articles

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Laurie DiMiceli, Swaminathan Padmanabhan, MD, David Lawrence, Zale P. Bernstein, MD, Kenichi Takeshita, MD, David Spaner, Paul Wallace, MD, Catriona Byrne, Cynthia Crystal, Myron S. Czuczman, MD

Blood (2005) 106 (11): 447.

https://doi.org/10.1182/blood.V106.11.447.447

Published: 2005

Journal Articles

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Laurie A. DiMiceli, Jihnee Yu, Zale P. Bernstein, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 2421.

https://doi.org/10.1182/blood.V104.11.2421.2421

Published: 2004

Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Myron S. Czuczman, MD, Marion Skipper, RN, Alice Mohr, NP, Zale P. Bernstein, MD, Philip McCarthy, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Alban Chanan-Khan, MD

Blood (2004) 104 (11): 1396.

https://doi.org/10.1182/blood.V104.11.1396.1396

Published: 2004

NARROW

CNS Involvement In A Patient with Waldenstrom’s Macroglobulinemia-A Diagnostic Challenge

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Inhibitor Eradication In Acquired Factor VIII Inhibitor: A Case Series

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

Lack of Impact on Platelet Increments by Number of Apheresis Platelet Units Transfused

Photopheresis in HIV-1 Infected Patients Utilizing (Benzoporphyrin Derivative Verteporfin/BPD-MA) and Light.

Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity.

Clinical Outcomes of Off-Label Use of Recombinant Activated Factor VII (rFVIIa) at Teaching Hospitals Affiliated with a Medical School.

Photopheresis in HIV-1 Infected Patients (Pt) Using Benzoporphyrin Derivative (BPD-MA) Induces Apoptosis in CD4 Cells, Increases Cytolytic T-Cell Activity, Intracellular Expression of Chemokines, and Decreases HIV Infectivity and Viral Load.

Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin (Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with Relapsed (rel) or Refactory (ref) Multiple Myeloma.

Assessment of Menorrhagia in Females Followed for Bleeding Disorders at the Hemophilia Center of Western New York-Correlation between Clinical Presentation and Laboratory Parameters.

Assessment of Menorrhagia in Females Followed for Bleeding Disorders at the Hemophilia Center of Western New York-Correlation between Clinical Presentation and Laboratory Parameters.

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

Photopheresis in HIV-1 Infected Patients (pt) Using Benzoporphyrin Derivative (BPD-MA) Induces Apoptosis in CD4 Cells, Increases Intracellular Expression of Chemokines and Decreases HIV Infectivity and Viral Load.

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only